Bivalirudin in acute coronary syndromes and percutaneous coronary intervention

Reviews in Cardiovascular Medicine

Volumn 7, Issue SUPPL. 3, 2006, Pages

  Lee, Michael S ^a   Makkar, Rajendra R ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Acute coronary syndrome; Bivalirudin; Heparin; Percutaneous coronary intervention; Thrombin

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; PLASMA PROTEIN; THROMBIN;

ACUTE CORONARY SYNDROME; ANTIBODY PRODUCTION; ANTICOAGULATION; ARTICLE; BINDING AFFINITY; BLEEDING; CLINICAL TRIAL; COST CONTROL; DOSE KIDNEY FUNCTION RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TARGETING; FIBRIN FORMATION; HEALTH CARE COST; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEMODIALYSIS; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; KIDNEY FAILURE; LOW DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN ANALYSIS; PROTEIN FUNCTION; THROMBOCYTE ACTIVATION; THROMBOGENESIS; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT DURATION;

ACUTE DISEASE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; CORONARY DISEASE; HIRUDINS; HUMANS; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; THROMBOSIS;

EID: 33846308521     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326:242-250.
2. Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N Engl J Med. 1992; 326:242-250.
3. Marmur JD. Direct versus indirect thrombin inhibition in percutaneous coronary intervention. J Invas Cardiol. 2002;14(suppl B): 8B-18B.
4. Liaw PCY, Becker DL, Stafford AR, et al. Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor II in the presence of dermatan sulfate but not heparin. J Biol Chem. 2001;276:20959-20965.
5. Xiao Z, Théroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation. 1998;97:251-256.
6. Lewis B. Thrombocytopenia and outcome in invasive cardiology. J Invas Cardiol. 2002; 14(suppl B):38B-47B.
7. Robson R, White H. Aylward P, Frampton C. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose and gender. Clin Pharmacol Ther. 2002;71:433-439.
8. Weitz JI, Crowther M. Direct thrombin inhibitors. Thromb Res. 2002;106:V275-V284.
9. Kleiman NS, Klein J, Fernandes LS, et al. Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide. Am Heart J. 2002;143:585-593.
10. Mehta S, Yebara SM, Ibrahim M, Reyes M. Cedars Medical Center's experience: early ambulation post PCI with use of direct thrombin inhibitor, bivalirudin. Cath Lab Digest. 2004;12:1-4.
11. Fox I, Dawson A, Loynds P, et al. Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans. Thromb Haemost. 1993;69: 157-163.
12. Minutello RM, Wong SC, Chou ET, et al. Angiomax facilitates early sheath removal after coronary angioplasty: the AFRICA Study [poster abstract]. Presented at: 15th Transcatheter Cardiovascular Therapeutics Meeting; September 15-19, 2003; Washington, DC. Poster abstract 340.
13. Mehta S, Yebara SM, Ibrahim M, et al. Mercy Medical Center's experience: early ambulation post PCI with use of direct thrombin inhibitor, bivalirudin. Cath Lab Digest. 2004;12:24-27.
14. Bittl JA, Chaitman BR, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or post-infarction angina: the final report of the Bivalirudin Angioplasty Study. Am Heart J. 2001;42:952-959.
15. Lincoff AM, Kleiman NS, Kottke-Marchant K, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J. 2002;143: 847-853.
16. Lincoff AM, Bittl JA, Kleiman NS, et al., for the REPLACE-1 Investigators. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol. 2004;93:1092-1096.
17. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853-863.
18. Antman EM. Should bivalirudin replace heparin during percutaneous coronary intervention? JAMA. 2003;289:853-863.
19. Lincoff AM, Kleiman NS, Kereiakes DJ, et al., for the REPLACE-2 Investigators. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/ IIIa blockade during percutaneous coronary revascularization: REPLACE-2 Randomized Trial. JAMA. 2004;292:696-703.
20. Chew DP, Lincoff AM, Gurm H, et al. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). Am J Cardiol. 2005;95:581-585.
21. Cohen DJ, Lincoff AM, Lavelle TA, et al. Economic evaluation of bivalirudin with provisional glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. J Am Coll Cardiol. 2004;44:1792-1800.
22. Gurm HS, Rajagopal V, Fathi R, et al. Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center. Am J Cardiol. 2005;95:716-721.
23. Stone GW, Bertrand M, Colombo A, et al. Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial: study design and rationale. Am Heart J. 2004;148:764-775.
24. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Available at: http://www.acc.org/clinical/guidelines/percutaneous/update/index.pdf. Accessed March 14, 2006.
25. Mahaffey KW, Lewis BE, Wildermann NM, ATBAT Investigators. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J Invas Cardiol. 2003;15:611-616.